Treatment of chronic myelogenous leukemia (CML) with c-myb antisense oligodeoxynucleotides
Gewirtz, A.M.
Bone Marrow Transplantation 14(Suppl 3): S57-S61
1994
ISSN/ISBN: 0268-3369 PMID: 7697011 Document Number: 431343
Document emailed within 1 workday
Related Documents
Szczylik, C.; Skórski, T.; Malaguarnera, L.; Hetman, J.; Chen, S.T.; Calabretta, B. 1996: Inhibition of in vitro proliferation of chronic myelogenous leukemia progenitor cells by c-myb antisense oligodeoxynucleotides Folia Histochemica et Cytobiologica 34(3-4): 129-134Rosti, V.; Bergamaschi, G.; Ponchio, L.; Cazzola, M. 1992: C-abl function in normal and chronic myelogenous leukemia hematopoiesis: in vitro studies with antisense oligomers Leukemia 6(1): 1-7
Mahon, F.X.; Ripoche, J.; Pigeonnier, V.; Jazwiec, B.; Pigneux, A.; Moreau, J.F.; Reiffers, J. 1995: Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction Experimental Hematology 23(14): 1606-1611
Geary, R.S.; Leeds, J.M.; Henry, S.P.; Monteith, D.K.; Levin, A.A. 1997: Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides Anti-Cancer Drug Design 12(5): 383-393
Guilhot, F. 1994: The role of interferon in the treatment of chronic myelogenous leukemia in chronic phase Nouvelle Revue Francaise d'Hematologie 36(Suppl 1): S39-S46
Cortes, J. 2012: Bosutinib in the treatment of chronic myelogenous leukemia Clinical Advances in Hematology and Oncology: H&o 10(11): 736-737
Guilhot, F. 1993: Interferon alfa and low-dose cytosine-arabinoside for the treatment of patients with chronic myelogenous leukemia in chronic phase. French CML Study Group Seminars in Hematology 30(3 Suppl 3: 24-25
Preisler, H.D.; Raza, A.; Higby, D.; Kirshner, J.; Woll, J.; Bennett, J.; Winton, L.; Weiner, R.; Richman, C.; Golomb, H. 1984: Treatment of myeloid blastic crisis of chronic myelogenous leukemia Cancer Treatment Reports 68(11): 1351-1355
Ohno, R. 2001: Treatment of chronic myelogenous leukemia with tyrosine kinase inhibitor Nihon Rinsho. Japanese Journal of Clinical Medicine 59(12): 2389-2394
Kantarjian, H.M.; Talpaz, M. 1994: Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemia Seminars in Oncology 21(6 Suppl 14: 8-13
Hirano, M.; Miura, M.; Kakizawa, H.; Morita, A.; Uetani, T.; Ohno, R.; Kawashima, K.; Nishiwaki, H.; Yamada, K. 1972: Treatment of chronic myelogenous leukemia with 3,3'-iminodi-1-propanol, dimethanesulfonate (ester), p-toluenesulfonate (NSC-140117) given orally Cancer ChemoTherapy Reports 56(3): 335-338
Reiffers, J.; Goldman, J.; Meloni, G.; Cahn, J.Y.; Gratwohl, A. 1994: Autologous stem cell transplantation in chronic myelogenous leukemia: a retrospective analysis of the European Group for Bone Marrow Transplantation. Chronic Leukemia Working Party of the EBMT Bone Marrow Transplantation 14(3): 407-410
Dhingra, K.; Talpaz, M.; Kantarjian, H.; Ku, S.; Rothberg, J.; Gutterman, J.U.; Kurzrock, R. 1991: Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression Leukemia 5(3): 191-195
Santos, G.W. 1988: Problems and strategies for bone marrow transplantation in acute leukemia and chronic myelogenous leukemia Cancer Detection and Prevention 12(1-6): 589-596
Shumak, K.H.; Baker, M.A.; Taub, R.N.; Coleman, M.S. 1980: Myeloblastic and lymphoblastic markers in acute undifferentiated leukemia and chronic myelogenous leukemia in blast crisis Cancer Research 40(11): 4048-4052
Anderson, J.K.; Moore, J.O.; Metzgar, R.S. 1979: Detection of both T-cell and Ia-like antigens on cells from patients with acute myelomonocytic leukemia and chronic myelogenous leukemia in blast crisis Cancer Research 39(12): 4810-4815
Boiziau, C.; Blonski, C.; Thuong, N.T.; Shire, D.; Toulme, J.J. 1991: Inhibition of reverse transcription by unmodified and modified antisense oligodeoxynucleotides Nucleic Acids Symposium Series 24: 121-125
Song, H.F.; Tang, Z.M. 2001: "Target secondary structural motif" in the action of antisense oligodeoxynucleotides Yao Xue Xue Bao 36(8): 585-589
Drobyski, W.R.; Roth, M.S.; Thibodeau, S.N.; Gottschall, J.L. 1992: Molecular remission occurring after donor leukocyte infusions for the treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation Bone Marrow Transplantation 10(3): 301-304
Tsuji-Takayama, K.; Kamiya, T.; Nakamura, S.; Matsuo, Y.; Adachi, T.; Tsubota, T.; Imanishi, J.; Minowada, J. 1994: Establishment of multiple leukemia cell lines with diverse myeloid and/or megakaryoblastoid characteristics from a single Ph1 positive chronic myelogenous leukemia blood sample Human Cell 7(3): 167-171